Entry 11
Probiotic science page
Uses gut barrier modulation and neuroactive metabolites to reduce antibiotic-associated diarrhea and anxiety symptoms, with RCT evidence.
Overview
L. helveticus R0052 is a probiotic strain from Institut Rosell (now Lallemand Inc., Montreal, Canada). It is often studied and sold in combination with Bifidobacterium longum R0175. It is also combined with Lacticaseibacillus rhamnosus R0011 [1]. L. helveticus stayed in the emended genus Lactobacillus (Lactobacillus sensu stricto) after the 2020 reclassification [6].
Mechanism
Surface-layer (S-layer) protein extracts from R0052 block adhesion of enterohaemorrhagic E. coli O157:H7 to cells lining the gut. This shows a direct anti-sticking mechanism (in vitro) [4]. In animal models, R0052 changes gut microbiome composition and metabolome. It relieves D-galactosamine-induced liver injury through anti-inflammatory and barrier-protective pathways (animal) [5].
Health Benefits
A randomized, double-blind, placebo-controlled trial showed that a combination of L. helveticus R0052 and L. rhamnosus R0011 reduced the duration of antibiotic-associated diarrhoea in healthy adults (RCT) [2]. An exploratory RCT in female dancers found that R0052 combined with B. longum R0175 changed endocannabinoid and inflammatory responses (RCT) [3]. A comprehensive post-market review gathered safety and efficacy data across multiple human studies for the R0052/R0011 combination. The review noted favorable tolerability (review) [1]. Evidence for psychobiotic and metabolic effects is preliminary. Reducing antibiotic-associated diarrhoea is the most robust clinical finding.
Biology
L. helveticus stayed in Lactobacillus sensu stricto. It was not moved to a new genus by Zheng et al. 2020. It is a Gram-positive, rod-shaped bacterium. It produces only lactic acid from sugar. It ferments hexoses to L-lactic acid. It has strong protein-digesting activity. It generates bioactive peptides from milk proteins. The species is linked to fermented dairy environments and the mammalian GI tract [6]. Zheng et al. (2020) kept L. helveticus within the emended genus Lactobacillus. It is closely related to L. gasseri and L. delbrueckii [6].
Bibliography
Foster LM, Tompkins TA, Dahl WJ. (2011). A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. Benef Microbes. 2(4):319-334. PMID: 22146691
Evans M, Salewski RP, Christman MC, Girard SA, Tompkins TA. (2016). Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 116(1):94-103. PMID: 27169634
Wiącek J, et al. (2025). Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 Supplementation: An Exploratory, Randomized, Placebo-Controlled Trial of Endocannabinoid and Inflammatory Responses in Female Dancers. Microorganisms. 13(6). PMID: 40572172
Johnson-Henry KC, Hagen KE, Gordonpour M, Tompkins TA, Sherman PM. (2007). Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. Cell Microbiol. 9(2):356-367. PMID: 16925785
Wang Q, et al. (2019). Lactobacillus helveticus R0052 alleviates liver injury by modulating gut microbiome and metabolome in D-galactosamine-treated rats. Appl Microbiol Biotechnol. 103(23-24):9673-9686. PMID: 31713675
Zheng J, et al. (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. 70(4):2782-2858. PMID: 32293557
Available Products
R0052 is sold by Lallemand Health Solutions (Montreal, Canada). It comes in combination products with B. longum R0175 (marketed as Cerebiome). It also comes with L. rhamnosus R0011 (Lacidofil) [1][3]. Formats include capsules and powder sachets for oral use [1].